causal

Rebates Create Floor Not Ceiling on Prices

Because commercial-plan rebates are reported at only 20-30% off a list price that has itself risen ~60% over four years, the post-rebate price still rises year over year and becomes a floor rather than a ceiling, against which new drugs can launch even higher and look cheap, and generics can drop just slightly and claim to be a bargain.

causalpending

Speaker

Robin Feldman

Evidence Quote

“that becomes a floor--you know, not really a ceiling; and new drugs can come out even higher than that and look cheap in comparison.”

Source

Robin Feldman on Drugs, Money, and Secret Handshakes— EconTalk
Created: 6/13/2026, 12:12:41 AM

Your notes

Loading notes...